Tag: risk-based monitoring

Immunobridging in Pediatric Populations: A Step-by-Step Regulatory Guide

August 7, 2025

Immunobridging in Pediatric Populations: A Step-by-Step Regulatory Guide Designing Pediatric Immunobridging the Right Way What Pediatric Immunobridging Is—and When Regulators Expect It Pediatric immunobridging lets you infer protection in children and adolescents from immune responses rather than run large, lengthy efficacy trials. The concept is simple: demonstrate that a younger cohort’s immune response—typically binding IgG…

Immunogenicity Assessments, Vaccine Clinical Trials

Vaccine Reactogenicity and Immune Profiles

August 6, 2025

digi

Vaccine Reactogenicity and Immune Profiles Making Sense of Vaccine Reactogenicity and Immune Profiles Reactogenicity vs Immunogenicity: What They Are—and Why Both Matter Reactogenicity describes short-term, expected local and systemic symptoms that follow vaccination (e.g., injection-site pain, swelling, fever, myalgia, headache). Immunogenicity captures the biological response intended by vaccination—binding antibodies (e.g., ELISA IgG GMT), neutralizing antibodies…

Immunogenicity Assessments, Vaccine Clinical Trials

Adaptive Designs in Rapid Vaccine Development

August 4, 2025

digi

Adaptive Designs in Rapid Vaccine Development Using Adaptive Trial Designs to Speed Vaccine Programs—Without Cutting Corners Why Adaptive Designs Fit Rapid Vaccine Development Adaptive designs let vaccine developers learn early and pivot quickly while protecting scientific credibility. In outbreaks or high-burden settings, waiting for fixed, multi-year trials can delay access. With pre-planned rules, sponsors can…

Phase I–IV Vaccine Trials, Vaccine Clinical Trials

Multi-Center Trials for Global Vaccine Evaluation

August 4, 2025

digi

Multi-Center Trials for Global Vaccine Evaluation Designing Global Multi-Center Vaccine Trials That Hold Up Everywhere Why Go Multi-Center and Global: Scientific, Statistical, and Regulatory Drivers Vaccine programs turn to multi-center, multi-country designs when they need speed, statistical power, and generalizability. Incidence varies across geographies and seasons; running across regions shortens accrual to reach event targets…

Phase I–IV Vaccine Trials, Vaccine Clinical Trials

Dosing Schedules and Booster Strategies

August 3, 2025

digi

Dosing Schedules and Booster Strategies Designing Vaccine Dosing Schedules and Smart Booster Plans Why Schedules and Boosters Matter: Balancing Biology, Safety, and Public Health Vaccine schedules and boosters translate immunology into public health impact. The interval between doses modulates germinal center maturation and class switching, while the decision to boost later counters waning immunity and…

Phase I–IV Vaccine Trials, Vaccine Clinical Trials

Accelerated Pathways for Vaccine Approval

August 3, 2025

digi

Accelerated Pathways for Vaccine Approval Navigating Accelerated Vaccine Approval Pathways Without Compromising Quality Why Accelerated Pathways Exist—and When They’re Appropriate Accelerated pathways exist to address serious, life-threatening, or public health emergency conditions where waiting for long, traditional development cycles would result in preventable morbidity and mortality. For vaccines, acceleration is justified when there is a…

Phase I–IV Vaccine Trials, Vaccine Clinical Trials

Ensuring Data Quality in Registry-Based Research

July 9, 2025

digi

Ensuring Data Quality in Registry-Based Research How to Ensure High-Quality Data in Registry-Based Research Registry-based research plays an increasingly vital role in generating real-world evidence (RWE) for pharmaceutical development, safety monitoring, and regulatory submissions. However, the impact of these registries hinges on one critical factor—data quality. Without clean, complete, and reliable data, a registry study…

Real-World Evidence (RWE) and Observational Studies, Registry Studies

Implementing a Risk-Based Approach to Source Data Verification (SDV)

June 20, 2025

digi

How to Apply a Risk-Based Approach to Source Data Verification (SDV) Traditional 100% Source Data Verification (SDV) is no longer the norm in modern clinical trials. With the advent of risk-based monitoring (RBM), sponsors and sites are adopting smarter, more targeted SDV practices. This guide explains how to implement a risk-based approach to SDV that…

Site Management and Monitoring, Source Data Verification

Combining Multiple Metrics for Composite Site Scores in Clinical Trials

June 11, 2025

digi

How to Combine Multiple Metrics into Composite Site Scores for Better Oversight Clinical trial performance management requires robust, data-driven tools to evaluate investigative sites. Sponsors and CROs increasingly rely on composite site scores, which combine several key performance indicators (KPIs) into a unified rating, to drive site selection, resource allocation, and oversight strategies. These composite…

Site Management and Monitoring, Site Performance Metrics

What is a Full-Service CRO in Clinical Trials? Explained with Services and Best Practices

June 10, 2025

digi

What is a Full-Service CRO in Clinical Trials? Explained with Services and Best Practices Understanding the Role and Scope of Full-Service CROs in Clinical Trials As the complexity and scale of drug development have increased, pharmaceutical companies have increasingly turned to Contract Research Organizations (CROs) to streamline the clinical trial process. Among them, the full-service…

Contract Research Organizations (CROs), Full-Service CROs